GlassScriptPhysician profile
David G Cassagnol
NPI 1316309024
$21,820.93
in general payments reported to CMS, 2019-2025
28 companies · $1,215 in 2025
The $1,215 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16K · 2021: $1,469 · 2022: $1,129 · 2023: $1,053 · 2024: $873 · 2025: $1,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,142.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $15,000.00 | 2020 | |
| Medtronic, INC. | $1,413.28 | 2021-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Vanta Adaptivestim |
| Boston Scientific Corporation | $1,000.03 | 2020-2024 | Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $870.11 | 2021-2025 | Relistor |
| Abbott Laboratories | $752.86 | 2021-2023 | Proclaim |
| Relievant Medsystems, INC. | $539.72 | 2020-2021 | |
| Abbvie INC. | $431.53 | 2022-2025 | Botox |
| Nevro Corp. | $308.18 | 2020-2024 | Senza |
| Bioventus LLC | $215.97 | 2023-2025 | Durolane, Gelsyn-3, Xcell |
| Ipsen Biopharmaceuticals, INC | $200.89 | 2022-2025 | Dysport |
| Lundbeck LLC | $196.07 | 2022-2024 | Vyepti |
| Globus Medical, INC. | $193.50 | 2025 | Senza |
| Saluda Medical Americas, INC. | $105.58 | 2023 | Evoke Scs |
| Si-Bone, INC. | $64.05 | 2024 | |
| Forte Bio-Pharma LLC | $58.96 | 2023-2025 | Prolate, Nalocet, Tanlor |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $57.23 | 2021-2025 | Xtampza |
| Valinor Pharma, LLC | $54.03 | 2025 | Movantik |
| Vertos Medical, INC. | $51.22 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $47.56 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $45.55 | 2025 | Xeomin |
| Depuy Synthes Sales INC. | $45.51 | 2023-2025 | Orthovisc, Monovisc |
| Zimmer Biomet Holdings, INC. | $44.57 | 2023 | Accufill |
| Alexion Pharmaceuticals, INC. | $28.66 | 2022 | |
| Stryker Corporation | $25.50 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $23.70 | 2022 | |
| Redhill Biopharma INC. | $16.59 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.14 | 2022 | |
| Mdd US Operations, LLC | $13.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cassagnol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.